Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 4: Clinical Pharmacy Services
4CPS-125
PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY
4CPS-124
MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE
4CPS-123
SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT
4CPS-122
ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION
4CPS-121
OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS
4CPS-120
EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS)
4CPS-119
A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN
4CPS-118
MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY
4CPS-117
UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?
4CPS-116
REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE
4CPS-115
CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB
4CPS-114
SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT
4CPS-113
THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
4CPS-112
ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT
4CPS-111
PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »
Follow Us